170 related articles for article (PubMed ID: 24242739)
21. The utility of PAX-2 in distinguishing metastatic clear cell renal cell carcinoma from its morphologic mimics: an immunohistochemical study with comparison to renal cell carcinoma marker.
Gokden N; Gokden M; Phan DC; McKenney JK
Am J Surg Pathol; 2008 Oct; 32(10):1462-7. PubMed ID: 18685487
[TBL] [Abstract][Full Text] [Related]
22. Papillary (chromophil) renal cell carcinoma: histomorphologic characteristics and evaluation of conventional pathologic prognostic parameters in 62 cases.
Amin MB; Corless CL; Renshaw AA; Tickoo SK; Kubus J; Schultz DS
Am J Surg Pathol; 1997 Jun; 21(6):621-35. PubMed ID: 9199639
[TBL] [Abstract][Full Text] [Related]
23. CD31 angiogenesis and combined expression of HIF-1α and HIF-2α are prognostic in primary clear-cell renal cell carcinoma (CC-RCC), but HIFα transcriptional products are not: implications for antiangiogenic trials and HIFα biomarker studies in primary CC-RCC.
Biswas S; Charlesworth PJ; Turner GD; Leek R; Thamboo PT; Campo L; Turley H; Dildey P; Protheroe A; Cranston D; Gatter KC; Pezzella F; Harris AL
Carcinogenesis; 2012 Sep; 33(9):1717-25. PubMed ID: 22777959
[TBL] [Abstract][Full Text] [Related]
24. Distinct immunophenotypes and prognostic factors in renal cell carcinoma with sarcomatoid differentiation: a systematic study of 19 immunohistochemical markers in 42 cases.
Yu W; Wang Y; Jiang Y; Zhang W; Li Y
BMC Cancer; 2017 Apr; 17(1):293. PubMed ID: 28449664
[TBL] [Abstract][Full Text] [Related]
25. Cyclin D1 expression as a prognostic factor in advanced hypopharyngeal carcinoma.
Nishimura G; Tsukuda M; Zhou LX; Furukawa S; Baba Y
J Laryngol Otol; 1998 Jun; 112(6):552-5. PubMed ID: 9764295
[TBL] [Abstract][Full Text] [Related]
26. Neovascularity as a prognostic marker in renal cell carcinoma.
Bauman TM; Huang W; Lee MH; Abel EJ
Hum Pathol; 2016 Nov; 57():98-105. PubMed ID: 27436827
[TBL] [Abstract][Full Text] [Related]
27. High expression of P53-induced Ring-h2 protein is associated with poor prognosis in clear cell renal cell carcinoma.
Wu XR; Sha JJ; Liu DM; Chen YH; Yang GL; Zhang J; Chen YY; Bo JJ; Huang YR
Eur J Surg Oncol; 2013 Jan; 39(1):100-6. PubMed ID: 23102595
[TBL] [Abstract][Full Text] [Related]
28. Prognostic significance of cyclin D1 and E-cadherin expression in laryngeal squamous cell carcinoma.
Ahmed RA; Shawky Ael-A; Hamed RH
Pathol Oncol Res; 2014 Jul; 20(3):625-33. PubMed ID: 24470282
[TBL] [Abstract][Full Text] [Related]
29. Renal Neoplasms With Overlapping Features of Clear Cell Renal Cell Carcinoma and Clear Cell Papillary Renal Cell Carcinoma: A Clinicopathologic Study of 37 Cases From a Single Institution.
Dhakal HP; McKenney JK; Khor LY; Reynolds JP; Magi-Galluzzi C; Przybycin CG
Am J Surg Pathol; 2016 Feb; 40(2):141-54. PubMed ID: 26752401
[TBL] [Abstract][Full Text] [Related]
30. Assessment of concomitant non-oncologic medication in patients with surgically treated renal cell carcinoma: impact on prognosis, cell-cycle progression and proliferation.
Neumann E; Klaiber P; Freitag K; Schwab M; Schaeffeler E; Hennenlotter J; Fend F; Kruck S; Scharpf M; Stenzl A; Bedke J; Rausch S
J Cancer Res Clin Oncol; 2019 Jul; 145(7):1835-1843. PubMed ID: 31006846
[TBL] [Abstract][Full Text] [Related]
31. Expression of cyclin D1, D3, E, and p27 in human renal cell carcinoma analysed by tissue microarray.
Hedberg Y; Ljungberg B; Roos G; Landberg G
Br J Cancer; 2003 May; 88(9):1417-23. PubMed ID: 12778072
[TBL] [Abstract][Full Text] [Related]
32. Down-regulation of PDCD4 expression is an independent predictor of poor prognosis in human renal cell carcinoma patients.
Li X; Xin S; Yang D; Li X; He Z; Che X; Wang J; Chen F; Wang X; Song X
J Cancer Res Clin Oncol; 2012 Mar; 138(3):529-35. PubMed ID: 22203471
[TBL] [Abstract][Full Text] [Related]
33. A promising biomarker to distinguish benign and malignant renal tumors: ELABELA.
Artas G; Kuloglu T; Dagli AF; Ugur K; Yardim M; Aydin S; Artas H; Kocdor H
Niger J Clin Pract; 2019 Mar; 22(3):386-392. PubMed ID: 30837428
[TBL] [Abstract][Full Text] [Related]
34. Immunohistochemical demonstration of cyclin D1 in bladder cancers as an inverse indicator of invasiveness but not an independent prognostic factor.
Takagi Y; Takashi M; Koshikawa T; Sakata T; Ohshima S
Int J Urol; 2000 Oct; 7(10):366-72. PubMed ID: 11144504
[TBL] [Abstract][Full Text] [Related]
35. Prognostic and diagnostic implications of epithelial cell adhesion/activating molecule (EpCAM) expression in renal tumours: a retrospective clinicopathological study of 948 cases using tissue microarrays.
Zimpfer A; Maruschke M; Rehn S; Kundt G; Litzenberger A; Dammert F; Zettl H; Stephan C; Hakenberg OW; Erbersdobler A
BJU Int; 2014 Aug; 114(2):296-302. PubMed ID: 24215118
[TBL] [Abstract][Full Text] [Related]
36. DOG1, cyclin D1, CK7, CD117 and vimentin are useful immunohistochemical markers in distinguishing chromophobe renal cell carcinoma from clear cell renal cell carcinoma and renal oncocytoma.
Zhao W; Tian B; Wu C; Peng Y; Wang H; Gu WL; Gao FH
Pathol Res Pract; 2015 Apr; 211(4):303-7. PubMed ID: 25596994
[TBL] [Abstract][Full Text] [Related]
37. A novel grading system for clear cell renal cell carcinoma incorporating tumor necrosis.
Delahunt B; McKenney JK; Lohse CM; Leibovich BC; Thompson RH; Boorjian SA; Cheville JC
Am J Surg Pathol; 2013 Mar; 37(3):311-22. PubMed ID: 23348209
[TBL] [Abstract][Full Text] [Related]
38. Low expression of p27(Kip1) is associated with tumor size and poor prognosis in patients with renal cell carcinoma.
Migita T; Oda Y; Naito S; Tsuneyoshi M
Cancer; 2002 Feb; 94(4):973-9. PubMed ID: 11920465
[TBL] [Abstract][Full Text] [Related]
39. Value of p53 as a prognostic marker in histologic subtypes of renal cell carcinoma: a systematic analysis of primary and metastatic tumor tissue.
Zigeuner R; Ratschek M; Rehak P; Schips L; Langner C
Urology; 2004 Apr; 63(4):651-5. PubMed ID: 15072872
[TBL] [Abstract][Full Text] [Related]
40. MicroRNA-194 is a Marker for Good Prognosis in Clear Cell Renal Cell Carcinoma.
Nofech-Mozes R; Khella HW; Scorilas A; Youssef L; Krylov SN; Lianidou E; Sidiropoulos KG; Gabril M; Evans A; Yousef GM
Cancer Med; 2016 Apr; 5(4):656-64. PubMed ID: 26860079
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
